{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T19:05:55Z","timestamp":1778526355445,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01497-1","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:30:00Z","timestamp":1735864200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy in thymic epithelial tumors: an attractive dilemma"],"prefix":"10.1007","author":[{"given":"Nahed","family":"Damaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal","family":"Chamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"1497_CR1","doi-asserted-by":"publisher","first-page":"1308989","DOI":"10.3389\/fonc.2023.1308989","volume":"13","author":"TS Gerber","year":"2023","unstructured":"Gerber TS, Strobl S, Marx A, Roth W, Porubsky S (2023) Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019. Front Oncol 13:1308989","journal-title":"Front Oncol"},{"key":"1497_CR2","doi-asserted-by":"publisher","unstructured":"Giaccone G (2000) Treatment of thymoma and thymic carcinoma. Ann Oncol 11(Suppl 3):245\u2013246. https:\/\/doi.org\/10.1093\/annonc\/11.suppl_3.245","DOI":"10.1093\/annonc\/11.suppl_3.245"},{"issue":"22","key":"1497_CR3","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","volume":"15","author":"N Girard","year":"2009","unstructured":"Girard N, Shen R, Guo T et al (2009) Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 15(22):6790\u20136799. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0644","journal-title":"Clin Cancer Res"},{"key":"1497_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/JTO.0000000000000215","volume":"9","author":"N Safieddine","year":"2014","unstructured":"Safieddine N, Liu G, Cuningham K et al (2014) Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. J Thorac Oncol 9:1018","journal-title":"J Thorac Oncol"},{"key":"1497_CR5","doi-asserted-by":"publisher","unstructured":"Thomas CR, Wright CD, Loehrer PJ (1999) Thymoma: state of the art. J Clin Oncol 17:2280\u20132289. https:\/\/doi.org\/10.1200\/JCO.1999.17.7.2280","DOI":"10.1200\/JCO.1999.17.7.2280"},{"issue":"Suppl","key":"1497_CR6","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG (2015) Thymic epithelial tumours: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl):v40\u2013v55","journal-title":"Ann Oncol"},{"key":"1497_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/08916930903555935","volume":"43","author":"A Marx","year":"2010","unstructured":"Marx A, Willcox N, Leite MI, Chuang WY, Schalke B, Nix W, Strobel P (2010) Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 43:413\u2013427 [CrossRef] [PubMed]","journal-title":"Autoimmunity"},{"key":"1497_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jtho.2022.01.021","volume":"17","author":"AC Roden","year":"2022","unstructured":"Roden AC, Ahmad U, Cardillo G, Girard N, Jain D, Marom EM, Marx A, Moreira AL, Nicholson AG, Rajan A et al (2022) Thymic Carcinomas-A Concise Multidisciplinary Update on recent developments from the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group. J Thorac Oncol 17:637\u2013650","journal-title":"J Thorac Oncol"},{"key":"1497_CR9","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1002\/cam4.4711","volume":"11","author":"WL Ma","year":"2022","unstructured":"Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Huang YL, Chang YL, Chang CH, Yang JC (2022) Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens. Cancer Med 11:3445\u20133456","journal-title":"Cancer Med"},{"key":"1497_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","volume":"126","author":"T Berghmans","year":"2018","unstructured":"Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte JJ, Meert AP, Moretti L, Ocak S, Roelandts M, Girard N (2018) Systemic treatments for thymoma and thymic carcinoma: a systematic review. Lung Cancer 126:25\u201331","journal-title":"Lung Cancer"},{"key":"1497_CR11","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1093\/annonc\/mdv382","volume":"26","author":"SD Martin","year":"2015","unstructured":"Martin SD, Coukos G, Holt RA, Nelson BH (2015) Targeting the undruggable: Immunotherapy meets personalized oncology in the genomic era. Ann Oncol 26:2367\u20132374","journal-title":"Ann Oncol"},{"key":"1497_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","volume":"474","author":"MW Rohaan","year":"2019","unstructured":"Rohaan MW, Wilgenhof S, Haanen J (2019) Adoptive cellular therapies: the current landscape. Virchows Arch 474:449\u2013461","journal-title":"Virchows Arch"},{"key":"1497_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","volume":"11","author":"P Sharma","year":"2021","unstructured":"Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP (2021) The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11:838\u2013857","journal-title":"Cancer Discov"},{"key":"1497_CR14","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL et al (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186:1652\u20131669","journal-title":"Cell"},{"key":"1497_CR15","first-page":"1","volume":"42","author":"EA Mittendorf","year":"2022","unstructured":"Mittendorf EA, Burgers F, Haanen J, Cascone T (2022) Neoadjuvant Immunotherapy: leveraging the Immune System to treat early-stage disease. Am Soc Clin Oncol Educ Book 42:1\u201315","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1497_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41577-019-0238-0","volume":"20","author":"N Kadouri","year":"2020","unstructured":"Kadouri N, Nevo S, Goldfarb Y, Abramson J (2020) Thymic epithelial cell heterogeneity: TEC by TEC. Nat Rev Immunol 20:239\u2013253","journal-title":"Nat Rev Immunol"},{"key":"1497_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","volume":"43","author":"A Marx","year":"2021","unstructured":"Marx A, Yamada Y, Simon-Keller K, Schalke B, Willcox N, Strobel P, Weis CA (2021) Thymus and autoimmunity. Semin Immunopathol 43:45\u201364","journal-title":"Semin Immunopathol"},{"key":"1497_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41590-018-0128-9","volume":"19","author":"M Cheng","year":"2018","unstructured":"Cheng M, Anderson MS (2018) Thymic tolerance as a key brake on autoimmunity. Nat Immunol 19:659\u2013664","journal-title":"Nat Immunol"},{"key":"1497_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"DR Wang","year":"2022","unstructured":"Wang DR, Wu XL, Sun YL (2022) Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response. Signal Transduct Target Ther 7:331","journal-title":"Signal Transduct Target Ther"},{"key":"1497_CR20","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard C, Ancion M, Delvenne P, Jerusalem G, Hubert P, Herfs M (2021) Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br J Cancer 125:927\u2013938","journal-title":"Br J Cancer"},{"key":"1497_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41577-023-00933-2","volume":"24","author":"A Cheng","year":"2024","unstructured":"Cheng A, Holland SM (2024) Anti-cytokine autoantibodies: mechanistic insights and disease associations. Nat Rev Immunol 24:161\u2013177","journal-title":"Nat Rev Immunol"},{"key":"1497_CR22","doi-asserted-by":"publisher","unstructured":"Zhao P, Li L, Jiang X (2019) Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy. J Hematol Oncol 12:1-14. https:\/\/doi.org\/10.1186\/s13045-019-0738-1Sekine","DOI":"10.1186\/s13045-019-0738-1Sekine"},{"key":"1497_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.21037\/med.2018.08.04","volume":"2","author":"I Sekine","year":"2018","unstructured":"Sekine I, Aida Y, Suzuki H (2018) Expression patterns and prognostic value of programmed death ligand-1 and programmed death 1 in thymoma and thymic carcinoma. Mediastinum 2:54","journal-title":"Mediastinum"},{"key":"1497_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.iotech.2019.09.002","volume":"3","author":"N Girard","year":"2019","unstructured":"Girard N (2019) Immune checkpoints in thymic epithelial tumors: challenges and opportunities. Immunooncol Technol 3:8\u201314","journal-title":"Immunooncol Technol"},{"key":"1497_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M et al (2018) The Integrated genomic Landscape of Thymic epithelial tumors. Cancer Cell 33:244\u2013258e10","journal-title":"Cancer Cell"},{"key":"1497_CR26","doi-asserted-by":"publisher","first-page":"101627","DOI":"10.1016\/j.esmoop.2023.101627","volume":"8","author":"K Kurokawa","year":"2023","unstructured":"Kurokawa K, Shukuya T, Greenstein RA, Kaplan BG, Wakelee H, Ross JS, Miura K, Furuta K, Kato S, Suh J et al (2023) Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open 8:101627","journal-title":"ESMO Open"},{"key":"1497_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s42003-020-1083-1","volume":"3","author":"AA Benitez","year":"2020","unstructured":"Benitez AA, Khalil-Aguero S, Nandakumar A, Gupta NT, Zhang W, Atwal GS, Murphy AJ, Sleeman MA, Haxhinasto S (2020) Absence of central tolerance in Aire-deficient mice synergizes with immune-checkpoint inhibition to enhance antitumor responses. Commun Biol 3:355","journal-title":"Commun Biol"},{"key":"1497_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.lungcan.2023.01.003","volume":"176","author":"A Arunachalam","year":"2023","unstructured":"Arunachalam A, Zhang I, Zhao B et al (2023) Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: a systematic literature review and meta-analysis. Lung Cancer 176:132","journal-title":"Lung Cancer"},{"key":"1497_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","volume":"16","author":"G Giaccone","year":"2021","unstructured":"Giaccone G, Kim C (2021) Durable response in patients with thymic carcinoma treated with Pembrolizumab after prolonged Follow-Up. J Thorac Oncol 16:483","journal-title":"J Thorac Oncol"},{"key":"1497_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejca.2022.12.005","volume":"180","author":"J Remon","year":"2023","unstructured":"Remon J, Villacampa G, Facchinetti F et al (2023) Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis. Eur J Cancer 180:117","journal-title":"Eur J Cancer"},{"key":"1497_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148 [CrossRef] [PubMed","journal-title":"Eur J Cancer"},{"key":"1497_CR32","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, Sun JM, Lee SH, Ahn JS, Park K et al (2019) Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol 37:2162\u20132170","journal-title":"J Clin Oncol"},{"key":"1497_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, McGuire C, Kallakury B, Chahine JJ, Manning M, Mogg R, Blumenschein WM, Tan MT et al (2018) Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 19:347\u2013355","journal-title":"Lancet Oncol"},{"key":"1497_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","volume":"78","author":"AL Mammen","year":"2019","unstructured":"Mammen AL, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R et al (2019) Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 78:150\u2013152","journal-title":"Ann Rheum Dis"},{"key":"1497_CR35","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH et al (2023) Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 29:3100\u20133110","journal-title":"Nat Med"},{"key":"1497_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","volume":"113","author":"Y Katsuya","year":"2019","unstructured":"Katsuya Y, Horinouchi H, Seto T et al (2019) Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 113:78","journal-title":"Eur J Cancer"},{"key":"1497_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","volume":"7","author":"A Rajan","year":"2019","unstructured":"Rajan A, Heery CR, Thomas A et al (2019) Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer 7:269","journal-title":"J Immunother Cancer"},{"key":"1497_CR38","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(22)00542-3","volume":"23","author":"F Conforti","year":"2022","unstructured":"Conforti F, Zucali PA, Pala L et al (2022) Avelumab plus Axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23:1287","journal-title":"Lancet Oncol"},{"key":"1497_CR39","doi-asserted-by":"publisher","first-page":"101576","DOI":"10.1016\/j.esmoop.2023.101576","volume":"8","author":"N Girard","year":"2023","unstructured":"Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M et al (2023) Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOPNIVOTHYMphaseIItrial. ESMO Open 8:101576","journal-title":"ESMO Open"},{"key":"1497_CR40","doi-asserted-by":"publisher","first-page":"814544","DOI":"10.3389\/fonc.2021.814544","volume":"11","author":"QD Thomas","year":"2021","unstructured":"Thomas QD, Basse C, Luporsi M, Girard N (2021) Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: a Case Report. Front Oncol 11:814544","journal-title":"Front Oncol"},{"key":"1497_CR41","doi-asserted-by":"publisher","first-page":"S1132","DOI":"10.1016\/j.annonc.2023.09.970","volume":"34","author":"H Shi","year":"2023","unstructured":"Shi H, Zhu H, Feng Y, Liu Y, Xing P, Hu X (2023) First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: a prospective, single-arm, phase II trial. Ann Oncol 34:S1132\u2013S1133","journal-title":"Ann Oncol"},{"key":"1497_CR42","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/ijc.31253","volume":"142","author":"Y Oji","year":"2018","unstructured":"Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M et al (2018) WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies. Int J Cancer 142:2375\u20132382","journal-title":"Int J Cancer"},{"key":"1497_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Perez-Gracia JL, Rodriguez-Ruiz ME, Ponz-Sarvise M, Castanon E (2019) Melero, I. cytokines in clinical cancer immunotherapy. Br J Cancer 120:6\u201315","journal-title":"Br J Cancer"},{"key":"1497_CR44","doi-asserted-by":"publisher","first-page":"e20647","DOI":"10.1200\/JCO.2023.41.16_suppl.e20647","volume":"41","author":"MJ McAdams","year":"2023","unstructured":"McAdams MJ, Swift S, Donahue RN, Celades C, Tsai YT, Bingham M, Szabo E, Zhao C, Sansone S, Choradia N et al (2023) Preliminary efficacy, safety, and immunomodulatory effects of PT-112 from a phase 2 proof of concept study in patients (pts) with thymic epithelial tumors (TETs). J Clin Oncol 41:e20647","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01497-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01497-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:20:20Z","timestamp":1735867220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01497-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":44,"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01497-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}